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Background: The established methods of antenatal screening for Down syndrome are based on immunoassay for
a panel of maternal serum biomarkers together with ultrasound measures. Recently, genetic analysis of maternal
plasma cell free (cf) DNA has begun to be used but has a number of limitations including excessive turn-around
time and cost. We aimed to develop an alternative method based on urinalysis that is simple, affordable and
accurate.
Method: 101 maternal urine samples sampled at 12–17 weeks gestation were taken from an archival collection of
2567 spot urines collected from women attending a prenatal screening clinic. 18 pregnancies in this set subsequently
proved to be Down pregnancies. Samples were either neat urine or diluted between 10 to 1000 fold in dH2O and
subjected to matrix assisted laser desorption ionization (MALDI), time of flight (ToF) mass spectrometry (MS). Data
profiles were examined in the region 6,000 to 14,000 m/z. Spectral data was normalised and quantitative
characteristics of the profile were compared between Down and controls.
Results: In Down cases there were additional spectral profile peaks at 11,000-12,000 m/z and a corresponding
reduction in intensity at 6,000-8,000 m/z. The ratio of the normalised values at these two ranges completely
separated the 8 Down syndrome from the 39 controls at 12–14 weeks. Discrimination was poorer at 15–17
weeks where 3 of the 10 Down syndrome cases had values within the normal range.
Conclusions: Direct MALDI ToF mass spectral profiling of maternal urinary has the potential for an affordable,
simple, accurate and rapid alternative to current Down syndrome screening protocols.
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Currently, prenatal screening for fetal Down syndrome
is based on the quantitative measurement of up to four
maternal serum biochemical markers (the principle
component being hCG) at 15–18 weeks of gestation or
two serum markers and ultrasound nuchal translucency
at 11–13 weeks of gestation. Increasingly, the latter ap-
proach is used because of a higher, 80-90%, detection
rate for a 5% false positive rate together with the option
of first trimester diagnosis and termination of affected
pregnancies [1].* Correspondence: ray@mapdiagnostics.co.uk
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unless otherwise stated.Recently cell free (cf) DNA, isolated from maternal
blood, has been developed as a new screening test for
Down syndrome with a greater than 99% detection rate
and less than 0.5% false positive rate [2]. Since this test
can substantially reduce the need for invasive prenatal
diagnosis, it is often described as a non-invasive prenatal
test (NIPT). Commercially available cfDNA tests will
also detect other common types of aneuploidy. They use
a variety of analytic methods including shotgun mas-
sively parallel sequencing, targeted sequencing and sin-
gle nucleotide polymorphisms together with complex
algorithms [3,4]. Technical limitations such as a turn-
around time exceeding a week, a high test failure rate,
and high cost [5] preclude immediate implementation in
a public health setting, although costs are reducing alls is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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quantifying cfDNA have been reported including meth-
ylated DNA-based approaches [6] and digital PCR [7].
In the mid 1990’s maternal urine analysis and in par-
ticular the quantitative immunoassay of hCGβcf was
proposed as an alternative to Down syndrome screening
based on maternal serum markers. Initial studies were
encouraging as maternal urine levels of women carrying
a fetal aneuploidy were on average 5–6 times higher
than pregnancies with non-aneuploid fetuses [8-14].
Thus, urinary hCGβcf was considered to be potentially
superior to serum hCG which was on average only in-
creased about two-fold. However, not only did hCGβcf
levels need to be corrected for gestational age, but ad-
justment had to be made for the dilutional effects of
water intake and urination [15]. This meant that simple
quantitated levels of hCGβcf per unit volume were so
variable that performance as a single screening marker
was not substantially greater, in terms of discriminatory
power, than existing serum based analysis [16-18].
Although this variability can be corrected for by
methods such as expressing levels as a ratio of another
urinary marker, such as creatinine, this did not prove
satisfactory. Indeed, since creatinine is influenced by
body mass and increased metabolism, it was never an
ideal correction factor for pregnant women. Although
other corrections are possible they were neither robust
nor sufficiently feasible to be practical [15].
Matrix Assisted Laser Desorption Ionisation Time of
Flight Mass Spectrometry (MALDI-ToF MS) can allow
the examination of genetic and metabolic diseases at the
level of protein expression and where posttranslational
modifications of specific proteins cause variations in
molecular mass to occur [19]. Therefore, proteomics
and genomics can be linked, helping in the diagnosis
and therapeutic monitoring of reproductive clinical dis-
orders [20].
Recently, we have used MALDI-ToF MS to identify
variation in the glycosylation that occurs in human
chorionic gonadotrophin beta core fragment (hCGβcf ),
following reports of an increase in hCG hyper glycosyla-
tion in Down syndrome pregnancies [21-23]. We
adopted a non-direct approach to analyse molecules in
the high-resolution range of 3,000 -5,000 m/z [22,24].
Differences in the mass spectral profile in this mass re-
gion were indicative of disorders in pregnancy [25].
Although we proposed that such variation might form
the basis of a clinical diagnostic test for abnormal pregnan-
cies, the purification of proteins from large urine collections
is not feasible in a clinical diagnostic situation. However,
the advances of MALDI-ToF MS instrumentation (with a
flight tube of 1 meter or more) can now resolve abundant
urinary molecules in the inferred mass region of 6,000 to
15,000 m/z without the need of any purification.We examined the mass spectral profiles of maternal
urinary metabolites in the 6,000 to 15,000 m/z region in
single, dH20 diluted, urine samples from pregnant
women with Down syndrome and those whose preg-
nancy was known not to be affected by fetal aneuploidy
(controls). The ability to use this post genomic mass
spectrometry approach as a potential rapid, robust and
affordable Down syndrome screening test was explored.
Results and discussion
Urine analysis has seen a resurgence of interest with the
advent of proteomics and metabolomics coupled to
technological developments in mass spectrometry tech-
niques [26,27]. Conceptually the focus is moving from a
quantitative measure of any given biomolecule(s) but to
compositional profiles [28,29] and the more subtle post
translational modification of proteins – the proteoform -
that are markers of a disease process [25].
Approaching the analysis of maternal urine with a
view that a qualitative structural change to a molecule,
rather than a quantitative change is the marker of dis-
ease, circumvents the problems associated with urine
analysis for Down syndrome highlighted twenty years
ago.
Visual examination of non-normalized MALDI-ToF
MS spectral profiles of maternal urine between ~5,000
and 16,000 m/z revealed substantial differences between
Down syndrome and controls. Figure 1 illustrates this
with the profiles of three Down syndrome cases and
one control. In Down syndrome there are additional
peaks at 11,000–12,000 m/z and apparent loss of peaks
at ~6,500–8,750 m/z. This effect was apparently greater at
12–14 than 15–17 weeks.
We have previously demonstrated that the post-
translational glycosylation of hCG produces a series of
glycoforms that are altered in placental disease and
when expressed by cancer [30-34]. Furthermore, these
glycoform differences are reflected in hCG’s major
urinary metabolite hCGβcf, which can be detected by
MALDI-ToF mass spectrometry [22,25]. However, it was
presumed that purification and often concentration of
the urine sample would be necessary [35,36]. Contrary
to this, since hCGβcf is the most abundant glycoprotein
in maternal urine we found that neat and preferably
dilution of maternal urine resulted in reproducible mass
spectral profiles in the mass regions expected for
hCGβcf.
In order to numerate the visual changes and compare
them statistically, the spectral data was captured between
6,000 m/z and 14,000 m/z. We choose to quantitate the
MALDI-ToF MS in bins of 100 m/z which allows for
huge variation in calibration and machine accuracy
(although MALDI is often quoted as <0.2% CV in























Figure 1 Example MALDI Tof mass spectral profiles of maternal urine between ~ 5,000 and 16,000 m/z. A: non-aneuploid pregnancy at
13,4 weeks gestation; B, C & D: Trisomy 21/Down syndrome, aneuploidy samples at 13,3 Weeks, 12,4 weeks and 16,6 weeks gestation. Large blue
arrows indicate regions of additional peaks at 11,000 – 12,000 m/z and the orthogonal stretched bracket indicate regions of ~ 6,500 – 8,750 m/z
that are less abundant in the Down syndrome samples.
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well as reducing the base-line, normalisation by the least
square method emphasised the peaks (see Figure 2).
The samples collected crossed a major maternal and
fetal-placental physiology boundary between the first
and 2nd trimester of pregnancy [37]. In order to seewhat affect this had on the mass spectral profile, normal-
ised spectral data was compared between samples at 12
and 17 weeks gestation in the non-aneuploidy pregnancy.
The median and associated variance of normalised spec-
tral area values were calculated at each of 100 m/z
bins between 6,000 and 14,000 m/z. As illustrated in
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Figure 2 Effect of normalisation of spectral intensity of an example urine sample at 5,000 to 15,000 m/z: Plot of blue line - % area
under the curve and black line - least square normalisation, of percentage intensity per 100 m/z bin units.
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Kruskall Wallis statistical analysis revealed significant
differences (p < 0.001) between the normalised sample
spectra as gestation age progressed. Indeed this indi-
cated that particular regions e.g. 7,000 – 8,000 and
8,900- 9,400 m/z were very variable (Figure 3A).
However, if the transition from first to 2nd trimester
was delineated by separating samples of 14 weeks
gestation or less from those of 15 weeks or greater;
Kruskall wallis analysis showed that there was no
significant differences in profile mass between the
normal non-aneuploid samples at any m/z bins if de-
lineated by a 14 week cut off: Examining pair-wise
comparisons, the normalised profiles at 12–14 weeks
gestation were remarkably consistent and clearly not
significantly different from each other (see Figure 3B).
Non-aneuploid pregnancy samples at 15, 16 and
17 weeks gestation were not significantly different
from each other however they were not as similar as
those of earlier gestation (see Figure 3C). Indeed, in
particular spectra of samples at 15 week gestation
approached, but did not reach statistical significant
differences from 16 and 17 week gestational samples
at 7,000 – 8,000 and 8,900 - 9,400 m/z.
Given the changes in profile with gestational age the
sample sets were divided into two groups; samples of 12
to 14 weeks gestation and samples of 15–17 weeks ges-
tation (see Table 1) for comparative analysis of profile
changes that were associated with a Down pregnancy.
Normalised spectral data was compared between 8
trisomy 21/Downs samples and 39 non-aneuploidy
pregnancy urine samples at 12–14 weeks of gestation
(see Figure 4). The % area under the curve and least
squared normalisation yielded near identical result
with marginally less variation around the medians for
the least squared normalised data. By plotting the
median values, 5th and 95th centiles as whiskers it wasevident that Down syndrome spectra varied signifi-
cantly from that of non-Down pregnancies (Kruskal wallis
test p < 0.001). Spectral values were dramatically lower
than those of non-aneuploidy samples at 6,000 to 8,000
mz and higher at ~9,400mz and 11,000 – 11,500 m/z
(Figure 4A). Creating a comparable quantitative nu-
merate value for the y measure meant that computa-
tional comparative scoring can be created. A simple
algorithm was created that distinguished Trisomy 21/
Down pregnancy from non-aneuploidy (score = y(m/z
11,400) + y(m/z 9,200) / y(m/z 6,700) with a 100% sen-
sitivity and specificity. Indeed, the margin of separation
was so large that seven-integer number cut off scores
could be applied with the same accuracy (see Figure 4B).
Normalised spectral data was also compared between
10 trisomy 21 Down samples and 44 non-aneuploidy
pregnancy urine samples at 15–17 weeks of gestation
(see Figure 5). The % area under the curve and least
squared normalisation yielded near identical results. By
plotting the median values, 5th and 95th centiles as
whiskers it was evident that Down syndrome spectral
values were still statistically different (p < 0.001) to those
of non-aneuploidy samples at 6,000 to 8,000 mz and the
profiles, whilst consistently lower, were merging in this
region (Figure 5A). However, values remained higher in
the Down samples at m/z of 11,000 to 12,000. Never-
theless, the comparable quantitative numerate values
for the y measure still meant that computational com-
parative scoring was still possible. In a simple algo-
rithm was created that distinguished Trisomy 21/
Down pregnancy from non-aneuploidy (score = Σy(m/z
11,300) to y(mz11,900)) with a 70% sensitivity and 100
specificity at 15–17 weeks gestation.
The experiments here demonstrate that no processing,
as we had previously employed [22,25], was necessary to
yield a sufficiently resolved spectra. This is due predom-
inately to using longer ToF flight tubes and advances in




Figure 3 Examination of the variability in m/z profiles from 84 non-aneuploid maternal urine samples as gestation progresses from 12
to 17 weeks of pregnancy. Plot of statistical significance comparisons (p-values) of each mass bin (every 100 m/z from 6000 to 14000 m/z) of
normalised data from maternal urinary MALDI – ToF mass spectral profiles. The red lines indicate a statistical significance cut off at p = 0.05.
Panel A – kruskall Wallis test comparison of all samples grouped from 12 – 18 weeks gestation, illustrating multiple m/z regions where there is a
difference between the profiles as gestation progresses; Panel B – step wise comparisons between 12, 13 and 14 week gestation samples,
illustrating that at these gestations there are no differences in the profiles of the non-aneuploid samples; Panel C – step wise comparisons
between 15, 16 and 17 week gestation samples, illustrating differences at specific m/z regions but none reach statistical significance at p < 0.05.
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Table 1 Maternal urine samples according to gestation
(nearest week) in Down syndrome and controls









Numbers in bold indicate subtotals at 12-14 and 15-17 weeks gestation.
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10,000 to 20,000 m/z range. Furthermore, rather than
rely on an operator subjective evaluation of a mass spec-
tra, MALDI-ToF mass spectra can be rendered semi-
quantitative such that automated quantification of the
qualitative change in the proteform pattern can be ana-
lysed. Also the spectral profiles in unaffected pregnan-
cies do not appear to differ markedly according to
gestational age in the first trimester of pregnancy, such
that exacting ultrasound dating would probably not be a
prerequisite of testing. While we acknowledge that the
samples are quite old, very little variability in this mass
region has been shown in stability studies. This is prob-
ably due to the nature of the molecules being examined,
and while hCG in urine does degrade into subunits [38]


















Figure 4 Comparison based on least squared normalization techniqu
gestation: A - shows overlaid average mass spectra with bin median
(black squares) and non-aneuploid (red circles) pregnancies at 6,000
B - a dot plot of the application of a simple predictive algorithm score call
6700) based on the spectral differences of the eight Down syndrome and
0% false positive rate.degrade when stored at −20°C, even for longer periods
of time. Even so, this may represent a significant limita-
tion to this study.
In summary, urinary mass spectral profiles differed in
the pattern of protein and glyco-peptide molecules de-
tected in the urine of women carrying a fetus with Down
syndrome. Focussing on simple MALDI-ToF analysis of
neat or diluted urine we propose a mass spectral pattern
analysis test that has the potential to achieve a very high
Down syndrome detection rate (>99%) with a low false
positive rate (<1%) in the first trimester of pregnancy. In
later second trimester performance was not as good with
3 of the Down samples being missed. In receiver oper-
ator plots a compromise of 90% detection for 6% false
positive can be achieved (data not shown); but larger
numbers of samples and more sophisticated scoring al-
gorithms would optimise this evaluation approach for
screening for Down syndrome.
We have used archival stored urine and a relatively
small series of Down syndrome cases so more studies on
fresh and diverse samples are needed. On the other hand
we have used a simple way of interpreting the spectral
profile as a ratio of areas under the curve and it is likely
that a more sophisticated mathematical model would
yield better result.
Such a proposed analytical approach has the distinct
advantages over current Down syndrome screening pro-
tocols in terms of turn-around time and ease of sample
collection. Results can be generated in minutes rather
than days and the patient can collect the sample at



























e for Down and non-aneuploid pregnancies at 12–14 weeks
as solid shapes and 5 and 95th centiles as whiskers for Down
to 14,000 m/z. The arrows indicate areas of maximal separation.
ed a Down Predictive Score = y(m/z 11400) + y(m/z 9200) / y(m/z
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Figure 5 Comparison (based on least squared normalization) of Down and non-aneuploid pregnancies at 15–17 weeks gestation:
A - shows overlaid average mass spectra with bin median as solid shapes and 5 and 95th centiles as whiskers for Down (black squares)
and non-aneuploid (red circles) pregnancies at 6000 to 14,000 m/z. The arrow indicates areas of maximal separation. B - a dot plot of the
application of a prediction algorithm score called a Down Predictive Score = Σ y(mz11300 to mz11900) based on the spectral differences of the
10 Down syndrome and 44 non-aneuploid samples indicating potential 70% detection for a 0% false positive rate.
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order to recover sufficient cfDNA, maternal blood sam-
pling must be after 10 weeks gestation and so requires
ultrasound dating. Even at later gestations, there is a test
failure rate largely due to insufficient fetal cfDNA in
samples. Turn-around time exceeds a week and with re-
peat testing, in some cases much longer. The commer-
cial cost of cfDNA testing varies from $900 to more
than $2500 in the USA and about half this in other
countries. Whilst cfDNA costs are reducing, the urinary
test we propose here would likely be a fraction of this
cost. Thus, the potential is for a MALDI–ToF mass




An archive of 2537 maternal urine sample was collected
in 1993–2000 from women attending a large teaching
hospital for Down syndrome screening. Participating
women were recruited to a research program designed
to investigate potential urinary markers of aneuploidy
[9-12]. A single early morning urine sample was col-
lected from each woman, aliquoted and stored at −80°C.
Urinary marker results were not used clinically. Informa-
tion on aneuploidy status was subsequently obtained
from the records of the local cytogentics laboratory. Per-
mission to access anonymized samples from the archived
set was granted by the ethics committee of Middlesex
University (Natural Sciences Ethical approval number
347).
For the current MALDI-ToF MS analysis 101 urine
samples at 12–17 weeks gestation were identified: 18were from Down syndrome pregnancies and 83 were
from unaffected controls. Table 1 shows the distribution
of gestations. The urine samples were removed from the
freezer and allowed to thaw on ice. Samples were centri-
fuged for 3 minutes at 1500 rpm in order to remove any
particulate debris and 100 μl aliquots prepared and re-
frozen at −20°C until used.
MALDI-ToF mass spectrometry
Steel MALDI plates (384 wells) were prepared by pipet-
ting 0.5 μl of sinapinic acid matrix solution (20 mg/ml
dissolved in 50/50 v/v acetonitrile (ACN)/ddH2O and
0.1% trifluoacetic acid (TFA)) and allowed to dry. 0.5 μl
of urine, and urine diluted 1/10 to 1/1000 in distilled
deionised water, was spotted on the dry matrix, followed
by the addition of a further 0.5 μl of sinapinic acid
matrix solution. This was allowed to dry at room
temperature for 1 hour before MALDI TOF MS
analysis.
The mass spectrometric analysis was carried out using
a Shimadzu Axima CFRplus MALDI mass spectrometer:
the pulse nitrogen laser (λmax = 337 nm), was fired at
90% power. The ions were accelerated by a 20 kV elec-
trical field down a 1.2 m linear tube and detected by a
micro-channel plate detector at a sampling rate of
500 MHz. Spectra were generated by summing 20–30
laser shots. A positive linear mode was used in order to
acquire the spectra.
Mass calibration was assigned using horse heart
cytochrome C at a concentration of 10 pmol/μl as an
external calibrant. The two points calibration gener-
ated was at [M + H]+ = 12 361 Da and [M + 2H]2+ =
6,181 Da for the spectral analysis of whole hCGβcf.
Iles et al. Clinical Proteomics  (2015) 12:9 Page 8 of 9Data was exported from the spectral fingerprint be-
tween 6,000-14,000 m/z.Spectral data normalisation
In order to compare the spectra, normalisation was ne-
cessary as Y axis values are relative to maximum signal
detected and not a measured scale. Thus, the algorithms
developed (below) and used in this study to normalise
the raw data allowed us to compare relative intensity
values in the spectra. Thus, data generated, peak mass
and intensity could all be compared and utilised in a
meaningful and automated computational manner. In
order to do this, the total area under the curve (which is
the integration of each sample within the mass range of
6,000-14,000 m/z) was calculated and the same region
was divided into 80 individual bins of 100 m/z unit.
The area under the curve of each bin was calculated
and expressed as a percentage of total spectral area under
the curve of 6000–14000 m/z based on the formula: Y %
difference ¼ y1−y refð Þy ref  100%, where y1 is the area value
at a given 100 m/z point (bin) and y ref is the total area
under the curve.
In an alternative normalization approach, the spectral
area relative intensity (Y Axis value) is calculated by the
“least square of difference “. In this method, the minimum
bin Y value of the spectra (y refmin) was subtracted from
the Y value at every 100 Da point (bin) and the difference
was squared. The formula used to calculate square of dif-
ference = (y1 − y refmin) ^ 2.Statistical analysis
The median and 5-95th centile range deviation of normal-
ized intensity values was calculated for Down syndrome
and control samples at each bin and for groups of bins
within a specified range. Statistical significance of the dif-
ference between these groups of samples was evaluated
using Kruskal-Wallis (Conover-Inman) and when appro-
priate, Mann–Whitney U tests.
Since the urine maternal and fetal physiology and
anatomy is continually changing with gestation [29,37],
any affect on spectral profile was assessed by comparing
the normalised values between 12–14 week and 15–17
week samples at each bin.
Data were recorded in Excel 2007 and statistical ana-
lyses performed with Stats-Direct™ software. Tests with
p ≤ 0.05 were classified as statistically significant.Competing interest
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